Tech

FDA Rejection Clouds Path For REGENXBIO's RGX-121

The FDA issued a Complete Response Letter for REGENXBIO's RGX-121 in MPS II, delaying the previously accelerated pathway and pressing for more robust data. The agency flagged questions about study design and surrogate endpoints, setting the stage for a resubmission and a Type A meeting to discuss next steps.

📅 February 10, 2026
⏱️ 2 min read
FDA Rejection Clouds Path For REGENXBIO's RGX-121

Key Takeaways

  • The FDA issued a CRL for RGX-121's BLA for MPS II, extending the PDUFA target date to February 8, 2026.
  • CRL cites concerns about study eligibility criteria and the suitability of a surrogate endpoint to predict clinical benefit.
  • REGENXBIO plans a Type A meeting and aims to resubmit with additional evidence from global experts.
  • Stock slid about 11% in premarket trading to roughly $9.17–$9.22 on the news.

People Involved

  • Myles R. MinterAnalyst

Entities Involved

  • REGENXBIO Inc. (RGNX)Biotech company developing RGX-121 for MPS II
  • Denali Therapeutics (DNLI)Biopharma company with another MPS II program
  • FDA - U.S. Food and Drug AdministrationRegulatory agency issuing the CRL

MarketMoodz Analysis

The CRL underscores how regulators balance speed with evidence in ultra-rare diseases. For investors, it signals that a successful accelerated approval hinges on robust, sometimes hard-to-collect data, meaning a longer commercialization timeline and higher funding needs if confirmatory trials become necessary.

Historically, FDA has rejected or delayed approvals in niche markets when endpoints are uncertain or trial designs struggle to enroll sparse patient populations. The Denali and RGX-121 contexts illustrate a broader regulatory tempo around MPS II—one that could constrain near-term upside while keeping a door open for later approval if the resubmission clears the key hurdles.

Watch for the Type A meeting outcome and the content of the resubmission, including any globally sourced expert consensus on neuronopathic MPS II. If the team can align on patient eligibility and meaningful endpoints, a path to approval could reopen, albeit with a longer lead time and higher resource needs.

Source: Original Article

Get AI-Powered Market Insights

Stay ahead of market-moving events with our real-time analysis and stock ratings.

Start Your Free Trial